Log In
Monday 21st May 2018

Problems with prostate screening

12th January 2010

A significant proportion of men who do not have prostate cancer test positive for the disease, according to a recent European trial.


The test measures levels of prostate-specific antigen (PSA) in male urine.

Because testing positively can mean that patients without the cancer have a biopsy or other unnecessary treatment, scientists and doctors are beginning to question the normal screening procedure for prostate cancer.

Other recent studies have shown that being screened may not be beneficial in the long term, and that men who take the test end up receiving too much treatment.

Recent data from the Finnish part of the European trial has shown that one in every eight men who receive the test will show up positive with no prostate cancer present. This holds even when the threshold for a positive result is raised considerably.

Meanwhile, the British Journal of Cancer reported that men who get a false positive are twice as likely not to agree to screening in the future even though they may be at risk of developing the disease.

Experts say more research is needed to make screening more accurate. They reminded people that the signs of prostate cancer can include having to rush to the toilet, difficulty in urinating, urinating more often than before, and pain, blood or semen in the urine.

Men with such symptoms should consult their doctor, or a urologist.

According to study lead author Tuomas Kilpelainen, routine screening was not advisable until scientists know more about the test and the effects it has.

While the UK currently has no organised prostate screening programme, the test is available on request, and its use is increasing.

According to Cancer Research UK's chief clinician, there are evidently two sides to the argument for the use of PSA testing.

Peter Johnson said it was important that older men be able to talk their doctors about the test, and make a decision about whether it is right for them.


Share this page


Jim French

Wednesday 3rd February 2010 @ 17:50

The prostate specific antigen test (PSA) is notoriously unreliable and costs the NHS money performing biopsies which are found to have been not required. After such a false alarm men are inclined not to want this procedure repeated and so place themselves at risk of future tumours being neglected.
Currently the Progensa PCA3 test which is performed on a urine sample can return informative rates of at least 94%. PCA3 is specifically over-expressed (66 fold) in PCa cells. This test is widely available throughout Europe and in the UK costs £300. If the NHS were to use this test it would, in many cases, save consultants from performing biopsies in cases where no further action was deemed necessary. This would save time and money surely.

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018